Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Phone416-679-0771
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$7.60 million
Profitability
Miscellaneous
Employees23
OptionableNot Optionable
Acerus Pharmaceuticals (TSE:ASP) Frequently Asked Questions
What is Acerus Pharmaceuticals' stock symbol?
Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."
When is Acerus Pharmaceuticals' next earnings date?
Has Acerus Pharmaceuticals been receiving favorable news coverage?
News headlines about ASP stock have trended positive on Monday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acerus Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Acerus Pharmaceuticals' key competitors?
Some companies that are related to Acerus Pharmaceuticals include Invion (IVX), Probiotec (PBP), Viridium Pacific Group (VIR), MMJ Group (MMJ), Indiva (NDVA), Cipher Pharmaceuticals (CPH), MGC Pharmaceuticals (MXC), ESSA Pharma (EPI), Aequus Pharmaceuticals (AQS), Cannpal Animal Therapeutics (CP1), NeutriSci International (NU), Lattice Biologics (LBL), Acreage (ACRGF), Amryt Pharma (AMYT) and Benchmark (BMK).
Who are Acerus Pharmaceuticals' key executives?
Acerus Pharmaceuticals' management team includes the folowing people:
- Ms. Patricia Symmes, Chief Operating Officer
- Dr. Nathan Bryson, Chief Scientific Officer
- Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
- Mr. Edward Gudaitis, Pres , CEO & Director
- Mr. Robert M. Motz, Chief Financial Officer
How do I buy shares of Acerus Pharmaceuticals?
Shares of ASP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Acerus Pharmaceuticals' stock price today?
One share of ASP stock can currently be purchased for approximately C$0.11.
How big of a company is Acerus Pharmaceuticals?
Acerus Pharmaceuticals has a market capitalization of C$25.88 million and generates C$7.60 million in revenue each year. Acerus Pharmaceuticals employs 23 workers across the globe.
What is Acerus Pharmaceuticals' official website?
How can I contact Acerus Pharmaceuticals?
The company can be reached via phone at 416-679-0771.
MarketBeat Community Rating for Acerus Pharmaceuticals (TSE ASP)
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASP will underperform the S&P 500 over the long term. You may vote once every thirty days.
